Biological therapies: new treatment options for ANCA-associated vasculitis? - Wikidata - awgldk - TriplyDB

Biological therapies: new treatment options for ANCA-associated vasculitis?

Biological therapies: new treatment options for ANCA-associated vasculitis?

http://www.wikidata.org/entity/Q36764935

about

Pathological role of fractalkine/CX3CL1 in rheumatic diseases: a unique chemokine with multiple functions.Biologic agents in systemic vasculitis.

P2860

Q35927383-38110C99-E9E1-4AD1-9F16-EFC1DC4A0E10 Q36934322-5A340390-E4A0-4BD8-9321-8D1A208E95BA

P2860

Biological therapies: new treatment options for ANCA-associated vasculitis?

http://www.wikidata.org/entity/Q36764935

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Biological therapies: new treatment options for ANCA-associated vasculitis?

@ast

Biological therapies: new treatment options for ANCA-associated vasculitis?

@en

type

label

Biological therapies: new treatment options for ANCA-associated vasculitis?

@ast

Biological therapies: new treatment options for ANCA-associated vasculitis?

@en

prefLabel

Biological therapies: new treatment options for ANCA-associated vasculitis?

@ast

Biological therapies: new treatment options for ANCA-associated vasculitis?

@en

P1433

Q36764935-2CA65FC1-8169-42CE-AE9D-A1C32E1986C8

P1476

Q36764935-90300371-B3E2-436D-8918-33A29281F410

P2093

Q36764935-2D943754-22C5-4B2D-9281-82973BFBE275

Q36764935-A2337AD7-620F-4130-8D02-64B24942DA48

Q36764935-A86CF0E4-2776-4779-B30D-B4D5746B4264

P2860

Q36764935-05E565E7-42A9-4B35-9E99-5C4D922FDE77

Q36764935-060364DA-93BD-401D-BF54-AEF258D24AE1

Q36764935-101C8103-1F87-474F-9B31-4987AF76417F

Q36764935-16D5DCCB-F9FF-46C3-BC8D-7A403694396E

Q36764935-21E3529F-B6D0-474D-885F-F0222C7C61DA

Q36764935-2F85CFAD-002A-46A7-929A-8A7B8329E67B

Q36764935-307D25CC-4122-4CB8-8FD9-52DD06319017

Q36764935-32F52D67-F9B0-4D85-9420-77A4BA299B2B

Q36764935-3D309865-0043-4A8D-8132-A29DE12ED1E2

Q36764935-4EA4E4C9-036E-437E-A7B3-4CB7CBC353DE

P304

Q36764935-E7E9093A-4188-4E2A-80CC-31CE6B084BF4

P31

Q36764935-6883B065-39AE-40D2-8514-1029418F6C2F

P356

Q36764935-5ED78CB1-5AEB-454A-A81C-890E5AB1AA43

P407

Q36764935-02D70514-18B4-40C6-8471-E121BBF4DF84

P433

Q36764935-957B9AA3-BCBB-4DC4-B5CA-5A6D91BBCD81

P478

Q36764935-0000376C-71C6-4700-B34D-AD4DC659CB2A

P577

Q36764935-F9DDF9EF-D806-4911-B378-EBFC0A156350

P5875

Q36764935-34F7CE60-95E7-4C68-8D3F-933FAEDDC65B

P698

Q36764935-5CC96785-75AE-4FAB-B116-813EC46B0033

P356

14712598.7.4.521

P1433

Expert Opinion on Biological Therapy

P1476

Biological therapies: new treatment options for ANCA-associated vasculitis?

@en

P2093

Peer M Aries

http://www.w3.org/2001/XMLSchema#string

Peter Lamprecht

http://www.w3.org/2001/XMLSchema#string

Wolfgang L Gross

http://www.w3.org/2001/XMLSchema#string

P2860

Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial.

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.

Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.

Etanercept plus standard therapy for Wegener's granulomatosis.

Churg-Strauss syndrome: update on recent developments.

Design of the Wegener's Granulomatosis Etanercept Trial (WGET).

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.

Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha.

P304

521-533

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.7.4.521

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6433292

http://www.w3.org/2001/XMLSchema#string

P698

17373903

http://www.w3.org/2001/XMLSchema#string